GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (LTS:0A50) » Definitions » Gross Margin %

Co-Diagnostics (LTS:0A50) Gross Margin % : 7.11% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Co-Diagnostics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Co-Diagnostics's Gross Profit for the three months ended in Mar. 2024 was $0.02 Mil. Co-Diagnostics's Revenue for the three months ended in Mar. 2024 was $0.25 Mil. Therefore, Co-Diagnostics's Gross Margin % for the quarter that ended in Mar. 2024 was 7.11%.

Warning Sign:

Co-Diagnostics Inc gross margin has been in long-term decline. The average rate of decline per year is -4.7%.


The historical rank and industry rank for Co-Diagnostics's Gross Margin % or its related term are showing as below:

LTS:0A50' s Gross Margin % Range Over the Past 10 Years
Min: 38.56   Med: 77.74   Max: 88.18
Current: 39.38


During the past 9 years, the highest Gross Margin % of Co-Diagnostics was 88.18%. The lowest was 38.56%. And the median was 77.74%.

LTS:0A50's Gross Margin % is ranked worse than
68.88% of 797 companies
in the Medical Devices & Instruments industry
Industry Median: 52.83 vs LTS:0A50: 39.38

Co-Diagnostics had a gross margin of 7.11% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Co-Diagnostics was -4.70% per year.


Co-Diagnostics Gross Margin % Historical Data

The historical data trend for Co-Diagnostics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics Gross Margin % Chart

Co-Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only 47.91 77.74 88.18 83.98 38.56

Co-Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.61 -131.82 89.58 16.51 7.11

Competitive Comparison of Co-Diagnostics's Gross Margin %

For the Medical Devices subindustry, Co-Diagnostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics's Gross Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Gross Margin % falls into.



Co-Diagnostics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Co-Diagnostics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=2.6 / 6.812
=(Revenue - Cost of Goods Sold) / Revenue
=(6.812 - 4.185) / 6.812
=38.56 %

Co-Diagnostics's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0 / 0.253
=(Revenue - Cost of Goods Sold) / Revenue
=(0.253 - 0.235) / 0.253
=7.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Co-Diagnostics  (LTS:0A50) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Co-Diagnostics had a gross margin of 7.11% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Co-Diagnostics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Co-Diagnostics (LTS:0A50) Business Description

Traded in Other Exchanges
Address
2401 South Foothill Drive, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.

Co-Diagnostics (LTS:0A50) Headlines

No Headlines